ZERIA PHARMCEUTICAL CO., LTD. Logo

ZERIA PHARMCEUTICAL CO., LTD.

Develops and distributes prescription & consumer healthcare products in Europe and Asia.

4559 | T

Overview

Corporate Details

ISIN(s):
JP3428850006
LEI:
Country:
Japan
Address:
中央区日本橋小舟町10番11号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Zeria Pharmaceutical Co., Ltd. is a comprehensive healthcare company engaged in the research, development, manufacturing, and distribution of pharmaceutical products. The company operates through two primary business segments: Ethical Pharmaceuticals (prescription drugs) and Consumer Healthcare (over-the-counter products). Its consumer product portfolio includes nutritional health drugs, remedies for gastrointestinal diseases, cold remedies, and ophthalmic solutions. Zeria actively expands its R&D pipeline by in-licensing and developing drugs with established sales records in overseas markets, distributing its products internationally across Europe and Asia.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-07 02:00
Registration Form
確認書
Japanese 8.4 KB
2025-11-07 02:00
Interim Report
半期報告書-第72期(2025/04/01-2026/03/31)
Japanese 202.1 KB
2025-07-03 07:19
Post-Annual General Meeting Information
臨時報告書
Japanese 23.2 KB
2025-06-26 03:01
Regulatory News Service
内部統制報告書-第71期(2024/04/01-2025/03/31)
Japanese 24.9 KB
2025-06-26 03:00
Regulatory News Service
確認書
Japanese 8.4 KB
2025-06-26 03:00
Annual Report
有価証券報告書-第71期(2024/04/01-2025/03/31)
Japanese 1.5 MB
2024-11-08 02:01
Report Publication Announcement
確認書
Japanese 8.3 KB
2024-11-08 02:00
Interim Report
半期報告書-第71期(2024/04/01-2025/03/31)
Japanese 204.2 KB
2024-07-03 03:44
Post-Annual General Meeting Information
臨時報告書
Japanese 23.8 KB
2024-06-27 07:11
Registration Form
確認書
Japanese 8.4 KB
2024-06-27 07:09
Governance Information
内部統制報告書-第70期(2023/04/01-2024/03/31)
Japanese 23.8 KB
2024-06-27 07:07
Annual Report
有価証券報告書-第70期(2023/04/01-2024/03/31)
Japanese 1.2 MB
2024-02-05 06:04
Quarterly Report
四半期報告書-第70期第3四半期(2023/10/01-2023/12/31)
Japanese 168.4 KB
2024-02-05 06:04
Report Publication Announcement
確認書
Japanese 8.3 KB
2023-11-06 07:10
Report Publication Announcement
確認書
Japanese 8.3 KB

Automate Your Workflow. Get a real-time feed of all ZERIA PHARMCEUTICAL CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ZERIA PHARMCEUTICAL CO., LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ZERIA PHARMCEUTICAL CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

LENZ Therapeutics, Inc. Logo
Develops a prescription eye drop for presbyopia, the age-related loss of near vision.
United States of America
LENZ
Lexaria Bioscience Corp. Logo
Biotech firm with patented technology improving oral drug delivery and absorption.
United States of America
LEXX
Lexeo Therapeutics, Inc. Logo
Develops AAV gene therapies for genetic cardiovascular and Alzheimer's diseases.
United States of America
LXEO
LEXICON PHARMACEUTICALS, INC. Logo
Develops gene-based drugs for chronic diseases, including treatments for heart failure.
United States of America
LXRX
LIFECORE BIOMEDICAL, INC. \DE\ Logo
A CDMO for parenteral drugs, producing injectable-grade sodium hyaluronate (HA).
United States of America
LFCR
Liminatus Pharma, Inc. Logo
Clinical-stage immuno-oncology firm developing cancer therapies targeting the CD47 checkpoint.
United States of America
LIMN
Lineage Cell Therapeutics Inc. Logo
Developing off-the-shelf cell therapies for neurological and ophthalmic conditions.
Israel
LCTX
Lipigon Pharmaceuticals AB Logo
Develops novel drugs for lipid metabolism disorders to reduce cardiovascular disease risk.
Sweden
LPGO
Lipocine Inc. Logo
Biopharma developing oral drugs for metabolic & endocrine disorders using delivery technology.
United States of America
LPCN
Lipum AB Logo
Develops first-in-class antibody treatments for chronic inflammatory diseases like arthritis.
Sweden
LIPUM

Talk to a Data Expert

Have a question? We'll get back to you promptly.